Affitech Appoints Sergej Kiprijanov New Head of Research.Appointment strengthens Company for future development of human antibody discovery technology and product candidates OSLO, Norway -- The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company's growth, Dr. Kiprijanov brings a wealth of experience in the antibody therapeutic field. Previously CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications. Welcoming the appointment, Affitech CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. Martin Welschof said, "Dr. Kiprijanov brings the experience and skillset Affitech requires as we start to improve our extremely promising MBAS MBAS Methylene-Blue active Substances and CBAS CBAS Command Budget Automated System CBAS Computrols Building Automation System (building automation software) CBAS Computerized Building Automation System CBAS Corporate Business Applications Support technologies and develop our product candidates. We are indeed delighted to have Sergej join our R&D team. I have known Sergej since he was a researcher at the German Cancer Research Center The German Cancer Research Center (known as the Deutsches Krebs Forschungs Zentrum or simply DKFZ in German), is a cancer research center based in Heidelberg, Germany. It is a member of the Helmholtz Association, the largest scientific organization in Germany. (DKFZ DKFZ Deutsches Krebsforschungszentrum (German Cancer Research Center, Heidelberg, Germany) ), Heidelberg, Germany, playing a key role in creating novel bispecific antibody formats for use in tumor therapy. He has generated an impressive number of publications and patents in the antibody field from his work both in the technology area as well as in development of antibody product candidates." Prior to moving to Germany, Dr. Kiprijanov headed the Laboratory of Cellular Engineering at the Russian State Research Center of Virology and Biotechnology "Vector" (Novosibirsk, Russia). Dr. Kiprijanov graduated in Biochemistry and Molecular Biology from Novosibirsk State University History Three fellow members of the USSR Academy of Sciences Lavrentiev, Sobolev, and Khristianovich, decided to bring international level research over the Urals from Moscow to the vast territories of Siberia. (Novosibirsk, Russia) in 1983 and received his Ph.D. degree from the Institute of Genetics and Selection of Industrial Microorganisms (Moscow, Russia) in 1990. Dr. Kiprijanov has authored more than 60 research articles, reviews and book chapters and is named as an inventor on 20 patents and patent applications. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion